

SOCS1 Methylation in Patients With Newly Diagnosed Acute Myeloid Leukemia

Chien-Yuan Chen,¹ Woei Tsay,¹ Jih-Luh Tang,¹ Hwei-Ling Shen,¹ Shu-Wha Lin,² Sheng-Yi Huang,¹ Ming Yao,¹ Yao-Chang Chen,^{1,2} Ming-Ching Shen,^{1,2} Chiu-Hwa Wang,^{1,2} and Hwei-Fang Tien^{1*}

¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

²Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

The proliferation and differentiation of hematopoietic precursor cells depend on various cytokines. The suppressor of cytokine signaling-1 (*SOCS1*) down-regulates Janus kinases/signal transducers and activators of transcription (*JAK/STAT*) pathway activity and inhibits the biological effects of cytokines. *SOCS1* has been shown to have tumor-suppressor activity, and methylation of this gene, resulting in transcriptional silencing, has been found in 65% of hepatocellular carcinoma and has been suggested to play an important role in the development of the cancer. The methylation status of the *SOCS1* gene in acute myeloid leukemia (AML) has not been reported before. In this study, we analyzed *SOCS1* methylation in 89 patients with newly diagnosed AML and correlated the result with immunophenotypes, cytogenetics, clinical features, and treatment outcome. *SOCS1* methylation was found in the leukemic cells from 53 patients (60%). Thirteen (76%) of the 17 patients with t(15;17) had *SOCS1* methylation, whereas this gene was methylated in only one (11%) of the nine patients with t(8;21). The frequencies of *SOCS1* methylation among various cytogenetic subgroups differed significantly ($P = 0.014$). Other clinical and laboratory parameters and the disease-free survival and overall survival were similar between patients with and without *SOCS1* methylation. In conclusion, *SOCS1* methylation occurs in more than half of AML cases, correlates with cytogenetic abnormalities, and may play an important role in the development of subsets of AML. © 2003 Wiley-Liss, Inc.

INTRODUCTION

The proliferation and differentiation of hematopoietic precursor cells are regulated by various cytokines (Lotem and Sachs, 2002). These cytokines act in part through activation of the Janus kinase/signal transducers and activators of transcription (*JAK/STAT*) pathway (Coffer et al., 2000; Ravandi et al., 2002). Inappropriate activation of the *STAT* signaling pathway may play an important role in the pathogenesis of leukemias (Coffer et al., 2000; Lin et al., 2000; Spiekermann et al., 2001, 2002). Constitutive activation of *STAT* transcription factors in acute myeloid leukemia (AML) is associated with short disease-free survival (Benekli et al., 2002). The suppressor of the cytokine signaling (SOCS) family of proteins negatively regulates cytokine signaling (Krebs and Hilton, 2001).

The members of the SOCS family (*SOCS1* to *SOCS7* and *CIS*) are composed of a poorly conserved amino-terminal region, a central SH2 domain, and a *SOCS* box (Hilton et al., 1998). *SOCS1* is a negative regulator of the *JAK/STAT* pathway (Yoshikawa et al., 2001). It inhibits the biological effects of various cytokines, including IL-2, IL-3, IL-4, IL-6, interferon (INF)- γ , and INF- α/β (Endo et al., 1997; Krebs and Hilton, 2001; O'shea et al., 2002). *SOCS1*-deficient mice die within the first 3 weeks of life from a myeloproliferative disorder,

which is driven by excessive IFN signaling (Naka et al., 1997; Starr et al., 1998). *SOCS1* expression results in suppression of IL-6 and leukemia inhibitory factor (LIF)-dependent *STAT3* activation in M1 leukemia cells (Suzuki et al., 1998). Cytokines such as IL-4, IL-13, INF- γ , LIF, and GM-CSF as well as IL-6 induce *SOCS1* gene expression in hematological cells (Naka et al., 1997; Starr et al., 1997). In vitro, the interactions between *SOCS1* and various cytokines in hematopoietic cells are complex. In vivo, the role for *SOCS1* in leukemia has not yet been investigated.

The expression of inducible *SOCS1* is associated with tumor-suppressor activity (Rottapel et al., 2002). Aberrant methylation of the *SOCS1* gene, which results in transcriptional silencing, was recently demonstrated in 17 of 26 human hepatocellular carcinomas (Yoshikawa et al., 2001). The res-

Supported by: The National Science Council of the Republic of China; Grant numbers: NSC 90-2314-B002-267 and 91-2314-B002-133.

*Correspondence to: Dr. Hwei-Fang Tien, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan.
E-mail: hftd@ha.mc.ntu.edu.tw

Received 29 October 2002; Accepted 25 February 2003

DOI 10.1002/gcc.10222

TABLE I. Clinical Characteristics of the 89 AML Patients Before Treatment

Variable	Total (n = 89)	SOCS1 Methylated (n = 53)	SOCS1 Unmethylated (n = 36)	P
Age				0.416
≥ 60	24	13	11	
< 60	65	40	25	
Sex (male/female)	54/35	32/21	22/14	0.111
White blood cell count (1000/mm ³) ^a		21.2 \pm 68.9	14.3 \pm 65.2	0.818
Hemoglobin (g/dl) ^a		8.1 \pm 2.2	7.4 \pm 2.8	0.529
Platelets (1000/mm ³) ^a		34.0 \pm 37.0	29.0 \pm 54.0	0.857
Lactate dehydrogenase (IU) ^a		1043 \pm 1373	927 \pm 1350	0.730
FAB subtype				0.278
M1	23	17 (74%)	6 (26%)	
M2	30	14 (47%)	16 (53%)	
M3	17	13 (77%)	4 (23%)	
M4	14	7 (50%)	7 (50%)	
M5	4	1 (25%)	3 (75%)	
M7	1	1 (100%)	0	
Cytogenetics ^b				0.122
Favorable	29	16	13	
Intermediate	50	30	20	
Unfavorable	8	6	2	

^aMedian \pm SD.

^bChromosomal study in two patients showed no metaphase cells for analysis. Favorable: including t(8;21), t(15;17), and inv(16). Unfavorable: t(7;11) (Huang et al., 1997) and complex chromosomal changes. Intermediate: Normal karyotype and other chromosomal abnormalities.

toration of *SOCS1* suppressed growth of tumor cells in which *SOCS1* was methylation-silenced (Yoshikawa et al., 2001). Aberrant DNA methylation in promoter regions of suppressor genes, including *HIC1* (Issa et al., 1997b), *WT1* (Plass et al., 1999), *CDKN2B* (Wong et al., 2000; Tien et al., 2001), and *CDKN2A* (Faderl et al., 2000), can be detected in AML and is usually associated with a poor prognosis and increased relapse rates. The incidence and the clinical and biological implications of *SOCS1* methylation in human AML are unknown. In this study, we analyzed the methylation status of the *SOCS1* gene in leukemic cells and correlated the result with the clinical and laboratory characteristics of 89 patients with newly diagnosed AML.

MATERIALS AND METHODS

Patients

The methylation status of the *SOCS1* CpG island was studied in bone marrow cells from 89 patients (54 men, 35 women) with newly diagnosed AML at the National Taiwan University from 1995 to 2000. Pretreatment characteristics are shown in Table 1. Eighty-two patients were adults and seven were children, and the median age was 48 years (range 1–85 years). The French–American–British (FAB) subtypes of AML included M1 (23 patients), M2 (30), M3 (17), M4 (14), M5 (4), and M7 (1).

Of the patients with AML other than the M3 subtype, most received conventional induction chemotherapy with cytarabine (AraC) for 7 days and one anthracycline (doxorubicin, idarubicin, or mitoxantrone) for 3 days. Some patients with old age and/or poor performance status received no treatment or only low dose AraC (10 mg/m²) for 14 to 21 days. The acute promyelocytic leukemia (APL) patients received all-*trans* retinoic acid with or without concurrent induction chemotherapy. After complete remission was achieved, the patients received consolidation chemotherapy with a conventional dose of AraC and one anthracycline or with high dose AraC (2 to 3 g/m²) twice a day for 3–4 days.

Immunophenotype

A panel of monoclonal antibodies to myeloid-associated antigens including CD13, CD33, CD11b, CD15, CD14, and CD41a, as well as lymphoid-associated antigens including CD2, CD5, CD7, CD19, CD10, and CD20, and lineage non-specific antigens HLA-DR, CD34, and CD56 was used to characterize the phenotypes of the leukemic cells. Expression of surface antigens on the leukemic cells was shown by an indirect immunalkaline phosphatase method as described before (Tien et al., 1993).

Cytogenetics

Chromosome analyses were carried out as described previously (Tien et al., 1995). Bone marrow (BM) cells were harvested directly or after 1–3 days of non-stimulated culture. Metaphase chromosomes were banded by trypsin-Giemsa and karyotyped according to the ISCN (Mitelman, 1995).

Methylation-Specific Polymerase Chain Reaction (PCR)

The methylation status of the promoter region of the *SOCS1* gene was analyzed by methylation-specific PCR as described (Herman et al., 1996; Tien et al., 2001). Mononuclear cells were isolated from BM aspirates by Ficoll-Hypaque gradient centrifugation. High-molecular-weight DNA was extracted. DNA (4 µg) in a volume of 40 µl was denatured by the addition of 10 µl of 1 mol/L NaOH (final concentration 0.2 mol/L) for 10 min at 37°C. Hydroquinone (30 µl of 10 mmol/L) (Sigma, St. Louis, MO) and 520 µl of 1.5 mol/L sodium bisulfite (Sigma) at pH 5 were added and mixed, and samples were incubated under mineral oil at 50°C for 16 hr. Modified DNA was purified by use of the Wizard DNA purification resin and Vacuum Manifold, according to the manufacturer's instruction (Promega, Madison, WI), and then eluted into 100 µl of water. Final desulfonation was achieved by treatment with 50 µl of 1 mol/L NaOH (final concentration 0.3 mol/L) at room temperature for 5 min, followed by ethanol precipitation. DNA was resuspended in 45 µl of water and used immediately or stored at -20°C before use.

The bisulfite-modified DNA was amplified by PCR with either a methylation-specific or unmethylation-specific primer set, designed by Yoshikawa et al. (2001). The methylation-specific primer sequences were 5'-TTC GCG TGT ATT TTT AGG TCG GTC-3' (sense) and 5'-CGA CAC AAC TCC TAC AAC GAC CG-3' (anti-sense). The unmethylation-specific primer sequences were 5'-TTA TGA GTA TTT GTG TGT ATT TTT AGG TTG GTT-3' (sense) and 5'-CAC TAA CAA CAC AAC TCC TAC AAC AAC CA-3' (antisense). Negative controls (normal DNA and distilled water) were used in each experiment. The hepatoma cell lines Hep3B and SNU423 were used as positive controls; the former had an amplified band in PCR with methylation-specific primers, but not in PCR with unmethylation-specific primers, and the latter had positive bands in both conditions. To avoid contamination,




Figure 1. Methylation-specific polymerase chain reaction analysis of the *SOCS1* promoter region in 12 patients with newly diagnosed AML (left panel: lanes 1 to 5 in experiment I; right panel: lanes 1 to 7 in experiment II). Five patients show *SOCS1* methylation (upper row, lanes 2 and 4 in experiment I; lanes 3, 5, and 6 in experiment II). Amplified bands of unmethylated DNA can also be seen in three of them (lower row: lanes 2 and 4 in experiment I; lane 6 in experiment II), but not in the other two. In experiment I, lane 6: normal control; lanes 7 and 8: hepatoma cell lines SNU-423 and Hep3B, respectively; lane 9: water.

each DNA sample was aliquoted and analyzed by use of at least two different PCRs.

Statistics

Comparisons were made with the t-test. Survival curves were plotted by use of the Kaplan–Meier method; differences between curves were analyzed by the log-rank test. All statistical analyses were performed by use of SPSS 8.0 for Windows (SPSS, Chicago, IL). Values of $P < 0.05$ were considered significant.

RESULTS

SOCS1 Methylation in AML and Its Correlation With Clinical Features

Methylation of the promoter region of the *SOCS1* gene was detected in 53 (60%) of the 89 patients with newly diagnosed AML (Fig. 1). Blood cells from eight normal donors of hematopoietic stem cells showed no methylation. The FAB M1 and M3 subtypes had higher incidences of *SOCS1* methylation (74 and 77%, respectively) than the M2, M4, and M5 subtypes (47, 50, and 25%, respectively; Table 1). However, the difference did not reach statistical significance (M1 and M3 vs. M2, M4, and M5: 75 vs. 46%, $P = 0.626$). Other clinical and laboratory features, including age, sex, white blood cell count, hemoglobin, platelets, and lactate dehydrogenase, were similar between patients with and without *SOCS1* methylation (Table 1). In addition to the amplified bands shown by PCR that used methylation-specific primers, samples from 49 of the 53 patients with *SOCS1* methylation could also be amplified with unmethylation-specific primers (Fig. 1). This may be explained by contamination of normal cells or the

TABLE 2. Correlation of *SOCS1* Methylation With Cytogenetic Results

Chromosome changes	Number of patients		P
	Total	With <i>SOCS1</i> methylation (%)	
t(8;21)	9	1 (11)	0.014
t(15;17)	17	13 (76)	
Inv(16)	3	2 (67)	
t(7;11)	3	2 (67)	
t(9;11)	2	1 (50)	
Trisomy 8 sole	5	4 (80)	
Simple ^a	21	12 (57)	
Complex ^a	5	4 (80)	
Normal	22	13 (59)	
Total ^b	87	52 (60)	

^aExcluding nonrandom abnormalities. Simple indicates three or fewer abnormalities and complex, four or more.

^bChromosomal study in two patients showed no metaphase cells for analysis.

presence of unmethylated alleles in the AML cells (Cameron et al., 1999; Tien et al., 2001).

Correlation of *SOCS1* Methylation With Cytogenetics and Immunophenotypes

The cytogenetic studies were performed before treatment. Two patients showed no metaphase cells for analysis. The cytogenetic result for the remaining 87 patients is shown in Table 2. The incidence of *SOCS1* methylation was low (11%) in AML with t(8;21), but high (76%) in APL with t(15;17); the difference among various cytogenetic subgroups was statistically significant ($P = 0.014$; Table 2).

The patients with *SOCS1* methylation had a somewhat lower incidence of HLA DR and CD11b expression on the leukemia cells than did those without methylation (63 vs. 82%, $P = 0.12$ and 21 vs. 38%, $P = 0.165$, respectively; Table 3). There was no difference in the expression of other antigens between the two groups of patients.

Correlation of *SOCS1* Methylation With Treatment Outcome

Among the 68 patients who received standard induction chemotherapy, 34 (83%) of the 41 patients with *SOCS1* methylation and 24 (89%) of the 27 without methylation obtained a complete remission (Table 4). The median disease-free survival was 15 months in the former group and 10 months in the latter group ($P = 0.97$). Also, the overall survival was not different between the two groups (median, 30 vs. 58 months, $P = 0.524$).

DISCUSSION

This is the first report concerning *SOCS1* methylation in AML. Sixty percent of newly diagnosed AML cases were identified to have aberrant methylation in the *SOCS1* CpG island. *SOCS1* is a negative regulator of the *JAK/STAT* signaling pathway, and inappropriate activation of JAK and STAT proteins has been associated with the oncogenic process (Bowman et al., 2000; Coffey et al., 2000). Direct implication of the *JAK/STAT* signaling pathway in human hematological malignancies has been demonstrated by the identification of translocations involving *JAK* and *STAT* encoding genes. For example, the *STAT5B* gene is fused to the retinoic acid receptor alpha (*RARA*) gene in an acute promyelocytic-like leukemia (Arnould et al., 1999), and a translocation involving the *JAK2* and *ETV6* genes, which results in constitutive activation of the *JAK2* protein tyrosine kinase, has been described in leukemia (Lacronique et al., 1997). *SOCS1* interferes with the *ETV6/JAK2*-induced phosphorylation and activates proteasome-dependent degradation (Frantsve et al., 2001). Moreover, the constitutive expression of *SOCS1* blocks the proliferation of cells transformed with *ETV6/JAK2*, *BCR/ABL*, or *v-ABL* (Rottapel et al., 2002). Dysregulation of the *SOCS1* gene may hence play a role in leukemogenesis.

The CpG islands of genes are essentially unmethylated in normal tissues (Bird, 1986), but become hypermethylated in some tumor-suppressor genes in malignancies, including leukemias (Issa et al., 1997a; John et al., 1999). Aberrant methylation of CpG islands is associated with gene inactivation (Singal and Ginder, 1999) and may contribute to the pathogenesis of neoplasia. *SOCS1* has been shown to have tumor-suppressor activity (Rottapel et al., 2002). Yoshikawa et al. (2001) demonstrated that aberrant methylation in the CpG island of the *SOCS1* gene resulted in its transcriptional silencing in hepatocellular carcinoma and that restoration of *SOCS1*-suppressed growth of tumor cells in which *SOCS1* was methylation-silenced and *JAK2* was constitutively activated. Because *SOCS1* methylation was demonstrated in most newly diagnosed AML, we suggest that *SOCS1* may collaborate with other genetic abnormalities to facilitate the development of leukemia.

It is noteworthy that the incidence of *SOCS1* methylation is different among the various cytogenetic subgroups, being higher in APL with t(15;17), and lower in AML with t(8;21). Because the signaling cascades in AML with different cytogenetic

TABLE 3. Surface Antigen Expression in Patients With and Without *SOCS1* Methylation

Marker (total number studied)	<i>SOCS1</i> methylated		<i>SOCS1</i> unmethylated		P
	No. studied	No. positive (%)	No. studied	No. positive (%)	
HLA DR (77)	49	31 (63)	28	23 (82)	0.120
CD13 (79)	49	44 (90)	30	26 (87)	0.724
CD33 (81)	51	47 (92)	30	25 (83)	0.280
CD11b (69)	43	9 (21)	26	10 (38)	0.165
CD14 (77)	49	7 (14)	29	6 (21)	0.536
CD15 (78)	48	36 (75)	30	20 (67)	0.449
CD41a (41)	24	1 (4)	17	0	1.000
CD19 (78)	48	5 (10)	29	4 (14)	0.722
CD7 (77)	48	12 (25)	29	9 (31)	0.604
CD2 (74)	47	6 (13)	27	3 (11)	1.000
CD34 (76)	49	32 (65)	27	14 (52)	0.328
CD56 (44)	25	6 (24)	19	7 (37)	0.507

TABLE 4. *SOCS1* Methylation and Treatment Outcome

Outcome	<i>SOCS1</i> methylated (n = 41)	<i>SOCS1</i> unmethylated (n = 27)	P
Complete remission (%)	34/41 (83%)	24/27 (89%)	0.242
Consolidation chemotherapy			0.579
Conventional regimen	29/41	13/27	
High dose regimen	12/41	14/27	
Stem cell transplantation	9	5	0.117
Disease-free survival (median, months)	15	10	0.245
Overall survival (median, months)	30	58	0.524

abnormalities are not fully understood, it is not clear why *SOCS1* methylation occurs frequently in some AMLs but not in others.

The *SOCS1* methylation had no impact on disease-free survival or overall survival in this study. Methylation of the CpG islands in *HIC1*, *WT1*, *CDKN2B*, and *CDKN2A* is associated with a poor outcome and a high relapse rate in patients with AML (Issa et al., 1997b; Plass et al., 1999; Faderl et al., 2000; Wong et al., 2000; Tien et al., 2001). In contrast, methylation of the estrogen receptor gene has been associated with improved prognosis in AML (Li et al., 1995). Thus, the correlation of CpG-island methylation and prognosis is still controversial, and the clinical implications of DNA methylation possibly depend on the function of the involved genes.

REFERENCES

- Arnould C, Philippe C, Bourdon V, Grégoire MJ, Berger R, Jonveaux P. 1999. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoid receptor alpha in acute promyelocytic-like leukemia. *Hum Mol Genet* 8:1741-1749.
- Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M. 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease free survival. *Blood* 99:252-257.
- Bird AP. 1986. CpG-rich islands and the function of DNA methylation. *Nature* 321:209-213.
- Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. *Oncogene* 19:2474-2488.
- Cameron EE, Baylin SB, Herman JG. 1999. p15^{INK4B} CpG-island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. *Blood* 94:2445-2451.
- Coffer PJ, Koenderman L, de Groot RP. 2000. The role of STATs in myeloid differentiation and leukemia. *Oncogene* 19:2511-2522.
- Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A. 1997. A new protein containing an SH2 domain that inhibits JAK kinase. *Nature* 387:921-924.
- Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. 2000. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. *Cancer* 89:1976-1982.
- Frantsve J, Schwaller J, Sternberg DW, Kutock J, Gilliland DG. 2001. SOCS-1 inhibits TEL-JAK2 mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. *Mol Cell Biol* 21:3547-3557.
- Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* 93:9821-9826.
- Hilton DJ, Richardson RT, Alexander WS, Viney EM, Wilson TA, Spring NS, Starr R, Nicholson SE, Metcalf D, Nicola NA. 1998. Twenty proteins containing a C-terminal SOCS box from five structural classes. *Proc Natl Acad Sci USA* 95:114-119.

- Huang SY, Tang JL, Liang YJ, Wang CH, Chen YC, Tien HF. 1997. Clinical, hematological and molecular studies in patients with chromosome translocation t(7;11): a study of four Chinese patients in Taiwan. *Br J Haematol* 96:682–687.
- Issa JP, Baylin SB, Herman JG. 1997a. DNA methylation changes in hematologic malignancies: biological and clinical implications. *Leukemia* 11:s7–s11.
- Issa JP, Zehnbauser BA, Kaufmann SH, Biel MA, Baylin SB. 1997b. HIC1 methylation is a late event in hematopoietic neoplasms. *Cancer Res* 57:1678–1681.
- John RM, Paul CV, Susan JC. 1999. Concurrent DNA methylation of multiple genes in acute myeloid leukemia. *Cancer Res* 59:3730–3740.
- Krebs DL, Hilton DJ. 2001. SOCS proteins: negative regulator of cytokine signaling. *Stem Cells* 19:378–387.
- Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. 1997. A TEL-Jak2 fusion protein with constitutive kinase activity in human leukemia. *Science* 278:1309–1312.
- Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, Issa JP. 1995. Estrogen receptor methylation is associated with improved survival in adult myeloid leukemia. *Clin Cancer Res* 5:1077–1084.
- Lin TS, Mahajan S, Frank DA. 2000. STAT signaling in the pathogenesis and treatment of leukemias. *Oncogene* 19:2496–2504.
- Lotem J, Sachs L. 2002. Cytokine control of developmental programs in normal hematopoiesis and leukemia. *Oncogene* 21:3284–3294.
- Mitelman F, editor. 1995. *ISCN: an international system for human cytogenetic nomenclature*. Basel: S. Karger.
- Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. 1997. Structure and function of a new STAT induced STAT inhibitor. *Nature* 387:924–929.
- O'shea JJ, Gadina M, Schreiber RD. 2002. Cytokine signaling in 2002: new surprises in the JAK/Stat pathway. *Cell* 109:S121–S131.
- Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA. 1999. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia: involvement of the WIT-1 gene. *Oncogene* 18:3159–3165.
- Ravandi F, Talpaz M, Kantarjian H, Estrov Z. 2002. Cellular signaling pathways: new targets in leukemia therapy. *Br J Haematol* 116:57–77.
- Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubrenil P, deSepulveda P. 2002. The tumor suppressor activity of SOCS-1. *Oncogene* 21:4351–4362.
- Singal R, Ginder GD. 1999. DNA methylation. *Blood* 93:4059–4070.
- Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. 2001. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. *Eur J Hematol* 67:63–71.
- Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. 2002. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. *Exp Hematol* 30:262–271.
- Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. 1997. A family of cytokine-inducible inhibitors of signaling. *Nature* 387:917–921.
- Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor cytokine signaling-1. *Proc Natl Acad Sci USA* 95:14395–14399.
- Suzuki R, Sakamoto H, Yasukawa H, Masuhara M, Wakioka T, Sasaki A, Yuge K, Komiya S, Inoue A, Yoshimura A. 1998. CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT 3 activation in M1 leukemia cells. *Oncogene* 17:2271–2278.
- Tien HF, Wang CH, Chen YC, Shen MC, Lin DT, Lin KH. 1993. Characterization of acute myeloid leukemia (AML) coexpressing lymphoid markers: different biologic features between T-cell antigen positive and B-cell antigen positive AML. *Leukemia* 7:688–695.
- Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, Chen YC, Shen MC, Lin KH, Lin DT. 1995. Correlation of cytogenetic results with immunophenotype, genotype, clinical features and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. *Cancer Genet Cytogenet* 84:60–68.
- Tien HF, Tang JL, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC, Shen MC. 2001. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukemic transformation. *Br J Haematol* 112:148–154.
- Wong IH, Ng MH, Huang DP, Lee JC. 2000. Aberrant p15 promoter methylation in adult and childhood acute leukemia of nearly all morphologic subtypes: potential prognostic implications. *Blood* 95:1942–1949.
- Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. *Nat Genet* 28:29–35.